THE DEAL, AT A GLANCE
From the announcementUpstream Biotechnology develops SwitchBlade
01What it doesUpstream Biotechnology develops SwitchBlade, a molecular control platform that regulates crop disease-resistance traits at the level of protein translation, so plants…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by LeVert Ventures, Corteva Catalyst, Silver Blue, VTC VenturesFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedUpstream Biotechnology develops SwitchBlade raised Seed, announced 2026-07-30From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersUpstream Biotechnology’s $0M Seed financing positions SwitchBlade as an early-stage Healthcare & Life Sciences asset entering a sector with broad recent capital activity…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Upstream Biotechnology develops SwitchBlade · Financing Record
Explore source-linked visual explanations for Upstream Biotechnology develops SwitchBlade. Unsupported claims are withheld while source review continues.
Record 9399 · Recorded date: 2026-07-30
Explore company records →